ESC 365 - Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial

ESC Professional Premium Access

Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial

Session: Lipid-lowering therapy and the atheroma

Topic: Pharmacotherapy

Speaker: Doctor S. Goodman (Toronto, CA)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)

1 presentation

0 follower

2 more presentations in this session

State-of-the-art lecture in lipid lowering therapy and the atheroma .

Speaker: Professor S. Nicholls (Melbourne, AU)

Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: Insights from the PACMAN-AMI randomized trial

Speaker: Doctor K. Koskinas (Bern, CH)

Access the full session

Lipid-lowering therapy and the atheroma

Speakers: Doctor S. Goodman, Professor S. Nicholls, Doctor K. Koskinas

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources